To report a case of amelanotic ciliochoroidal melanoma in a patient with oculocutaneous albinism. A 76-year-old Caucasian male with a past medical history of oculocutaneous albinism and recurrent urothelial carcinoma was found to have a mass in the left eye, suspicious for ciliochoroidal melanoma. On examination, visual acuity was 20/400 in both eyes (OU). External examination showed iris transillumination defects. Funduscopic examination OU revealed blonde fundus, optic nerve hypoplasia, and foveal hypoplasia, confirmed on optical coherence tomography. Funduscopic examination of the left eye revealed an inferonasal amelanotic ciliochoroidal mass, measuring 12.0 mm × 13.0 mm × 8.8 mm. There was visible intrinsic tumor vasculature and overlying subretinal fluid. B-scan ultrasonography demonstrated a hypoechoic, dome-shaped mass. The clinical and imaging features were consistent with amelanotic ciliochoroidal melanoma. The patient was treated with iodine-125 plaque radiotherapy. At the 4-month follow-up, the tumor demonstrated regression from 8.8 mm to 3.2 mm in thickness. Despite the apparent lack of uveal pigmentation, patients with oculocutaneous albinism can develop uveal melanoma.

1.
Grønskov
K
,
Ek
J
,
Brondum-Nielsen
K
.
Oculocutaneous albinism
.
Orphanet J Rare Dis
.
2007
Nov
;
2
(
1
):
43
.
[PubMed]
1750-1172
2.
Streutker
CJ
,
McCready
D
,
Jimbow
K
,
From
L
.
Malignant melanoma in a patient with oculocutaneous albinism
.
J Cutan Med Surg
.
2000
Jul
;
4
(
3
):
149
52
.
[PubMed]
1203-4754
3.
Luande
J
,
Henschke
CI
,
Mohammed
N
.
The Tanzanian human albino skin. Natural history
.
Cancer
.
1985
Apr
;
55
(
8
):
1823
8
.
[PubMed]
0008-543X
4.
Shields
CL
,
Frey
DM
,
Pagano
W
,
Shields
JA
.
Choroidal melanoma in a patient with oculocutaneous albinoidism
.
Retina
.
2006
;
10
:
10
.0275-004X
5.
Kheterpal
S
,
Shields
JA
,
Shields
CL
,
De Potter
P
,
Ehya
H
,
Eng
KY
.
Choroidal melanoma in an African-American albino
.
Am J Ophthalmol
.
1996
Dec
;
122
(
6
):
901
3
.
[PubMed]
0002-9394
6.
Casswell
AG
,
McCartney
AC
,
Hungerford
JL
.
Choroidal malignant melanoma in an albino
.
Br J Ophthalmol
.
1989
Oct
;
73
(
10
):
840
5
.
[PubMed]
0007-1161
7.
Harasymowycz
P
,
Boucher
MC
,
Corriveau
C
,
Gauthier
D
,
Allaire
G
.
Choroidal amelanotic melanoma in a patient with oculocutaneous albinism
.
Can J Ophthalmol
.
2005
Dec
;
40
(
6
):
754
8
.
[PubMed]
0008-4182
8.
Kaliki
S
,
Shields
CL
.
Uveal melanoma: relatively rare but deadly cancer
.
Eye (Lond)
.
2017
Feb
;
31
(
2
):
241
57
.
[PubMed]
0950-222X
9.
Okoro
AN
.
Albinism in Nigeria. A clinical and social study
.
Br J Dermatol
.
1975
May
;
92
(
5
):
485
92
.
[PubMed]
0007-0963
10.
Brenner
M
,
Hearing
VJ
.
The protective role of melanin against UV damage in human skin
.
Photochem Photobiol
.
2008
May-Jun
;
84
(
3
):
539
49
.
[PubMed]
0031-8655
11.
Okulicz
JF
,
Shah
RS
,
Schwartz
RA
,
Janniger
CK
.
Oculocutaneous albinism
.
J Eur Acad Dermatol Venereol
.
2003
May
;
17
(
3
):
251
6
.
[PubMed]
0926-9959
12.
Lookingbill
DP
,
Lookingbill
GL
,
Leppard
B
.
Actinic damage and skin cancer in albinos in northern Tanzania: findings in 164 patients enrolled in an outreach skin care program
.
J Am Acad Dermatol
.
1995
Apr
;
32
(
4
):
653
8
.
[PubMed]
0190-9622
13.
Nishigori
C
,
Yasumizu
M
,
Kawaguchi
M
, Tomoya Takata et al.
Malignant skin tumors in patients with oculocutaneous albinism
.
J Pigment Disord
.
2015
;
2
(
10
).2376-0427
14.
Ihn
H
,
Nakamura
K
,
Abe
M
,
Furue
M
,
Takehara
K
,
Nakagawa
H
, et al.
Amelanotic metastatic melanoma in a patient with oculocutaneous albinism
.
J Am Acad Dermatol
.
1993
May
;
28
(
5 Pt 2
):
895
900
.
[PubMed]
0190-9622
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.